246 related articles for article (PubMed ID: 21822009)
1. Molecular and cellular evidence for the alternative lengthening of telomeres (ALT) mechanism in chicken.
O'Hare TH; Delany ME
Cytogenet Genome Res; 2011; 135(1):65-78. PubMed ID: 21822009
[TBL] [Abstract][Full Text] [Related]
2. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
3. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
4. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
[TBL] [Abstract][Full Text] [Related]
5. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
[TBL] [Abstract][Full Text] [Related]
6. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
7. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.
Jiang WQ; Zhong ZH; Henson JD; Reddel RR
Oncogene; 2007 Jul; 26(32):4635-47. PubMed ID: 17297460
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.
Perrem K; Colgin LM; Neumann AA; Yeager TR; Reddel RR
Mol Cell Biol; 2001 Jun; 21(12):3862-75. PubMed ID: 11359895
[TBL] [Abstract][Full Text] [Related]
9. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
Yeager TR; Neumann AA; Englezou A; Huschtscha LI; Noble JR; Reddel RR
Cancer Res; 1999 Sep; 59(17):4175-9. PubMed ID: 10485449
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
[TBL] [Abstract][Full Text] [Related]
11. Telomere recombination requires the MUS81 endonuclease.
Zeng S; Xiang T; Pandita TK; Gonzalez-Suarez I; Gonzalo S; Harris CC; Yang Q
Nat Cell Biol; 2009 May; 11(5):616-23. PubMed ID: 19363487
[TBL] [Abstract][Full Text] [Related]
12. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies.
Fasching CL; Bower K; Reddel RR
Cancer Res; 2005 Apr; 65(7):2722-9. PubMed ID: 15805271
[TBL] [Abstract][Full Text] [Related]
14. The MUS81 endonuclease is essential for telomerase negative cell proliferation.
Zeng S; Yang Q
Cell Cycle; 2009 Jul; 8(14):2157-60. PubMed ID: 19617716
[TBL] [Abstract][Full Text] [Related]
15. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles.
Plantinga MJ; Pascarelli KM; Merkel AS; Lazar AJ; von Mehren M; Lev D; Broccoli D
Mol Cancer Res; 2013 Jun; 11(6):557-67. PubMed ID: 23505069
[TBL] [Abstract][Full Text] [Related]
16. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation.
Chung I; Leonhardt H; Rippe K
J Cell Sci; 2011 Nov; 124(Pt 21):3603-18. PubMed ID: 22045732
[TBL] [Abstract][Full Text] [Related]
17. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
[TBL] [Abstract][Full Text] [Related]
18. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism.
Venturini L; Daidone MG; Motta R; Collini P; Spreafico F; Terenziani M; Piva L; Radice P; Perotti D; Zaffaroni N
Genes Chromosomes Cancer; 2011 Oct; 50(10):823-9. PubMed ID: 21769957
[TBL] [Abstract][Full Text] [Related]
19. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells.
Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ
Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944
[TBL] [Abstract][Full Text] [Related]
20. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
